REFERENCES

1] Faugere M-C, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, Malluche HH. Improved Assessment of Bone Turnover by the PTH-(1-84)/large C-PTH Fragments Ratio in ESRD Patients. Kidney Int 2001; 60:1460-1468.

[2] Tokumoto, A. Case Study of Patient with Adynamic Low Bone Turnover Disease that Eluded Diagnosis – Comparison of PTH Ratio with Other Markers of Bone Turnover. J Am Soc Nephrol 2003(Nov); 14:596.

[3]. Tokumoto, A. Bone Histology Validation of the Scantibodies 1-84 PTH (CAP) Assay and the 1-84 PTH/Large C Terminal PTH Fragments Ratio. J Am Soc Nephrol 2003(Nov); 14:700.

[4] Tokumoto, A. 22-Oxa-Calcitriol (Maxacalcitol) Does Not Have the Same Suppressive Actions on 1-84 PTH and Large C Terminal PTH Fragments. J Am Soc Nephrol 2003(Nov); 14:701.

[5] Tokumoto, A. Superior Assessment of Bone Turnover in ESRD Patients by the 1-84 PTH/Large C Terminal PTH Fragments Ratio – A Bone Biopsy Study. J Am Soc Nephrol 2003(Nov); 14:702.

[6] Tokumoto, A. Bone Histology and Assessment of the Intact PTH Assay in 167 ESRD Patients. J Am Soc Nephrol 2003(Nov); 14:703.

[7] Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Gao P, Cantor T, Dusso A. A Novel Mechanism for Skeletal Resistance in Uremia. Kidney Int 2000; 58:753-761.

[8] Divieti P, John MR, Juppner H, Bringhurst FR. Human PTH-(7-84) Inhibits Bone Resorption in Vitro Via Actions Independent of the Type 1 PTH/PTHrP Receptor. Endocrinology 2002; 143(1):171-176.

[9] Langub MC, Monier-Faugere M-C, Wang G, Williams JP, Koszewski NJ, Malluche HH. Administration of PTH-(7-84) Antagonizes the Effects of PTH-(1-84) on Bone in Rats with Moderate Renal Failure. Endocrinology 2003; 144(4):1135-1138.

[10] Silverberg S, Gao P, Brown I, Logerfo P, Cantor T, Bilezikian J. Clinical Utility of an Immunoradiometric Assay for Parathyroid Hormone (1-84) in Primary Hyperparathyroidism. J Clin Endocrinol Metab 2003; 88(10):4725-4730.

[11] Gao, P, Scheibel S, D’Amour P, John M, Rao S, Schmidt-Gayk H, Cantor T. Development of a Novel Immunoradiometric Assay Exclusively for Biologically Active Whole Parathyroid Hormone 1-84: Implications for Improvement of Accurate Assessment of Parathyroid Function. J Bone Miner Res 2001; 16(4):605-614.

[12] Sawaya BP, Butros R, Naqvi S, Zhaopo G, Mawad H, Friedler R, Fanti P, Faugere M-C, Malluche HH. Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease. Kidney Int 2003; 64:737-742.

[13] Mittalhenkle A, Meligro C, Sherrard D. The Changing Relationship between Intact Parathyroid Hormone (iPTH) and Bone Histology in Dialysis Patients. J Am Soc Nephrol 2003(Nov); 14:558.

[14] Waller S, Ridout D, Cantor T, Rees L. Parathyroid Hormone (PTH) in Children w/Chronic Renal Failure; characterization of the 1-84 PTH:C-PTH Ratio. J Am Soc Nephrol 2003(Nov); 14:695.

[15] Waller S, Ridout D, Cantor T, Rees, L. Parathyroid Hormone (PTH) in Children w/Chronic Renal Failure; relationship between the 1-84PTH:C-PTH Ratio and Growth. Poster for ASN, 2003, San Diego, CA, J Am Soc Nephrol 2003(Nov); 14:694.

[16] Waller S, Reynolds A, Ridout D, Cantor T, Gao P, Rees, L. Parathyroid Hormone and its Fragments in Children with Chronic Renal Failure. Ped Nephrol 2003; 18:1242-1248.

[17] Salomon R, Charbit M, Gagnadoux M-F, Niaudet P, Gao P, Cantor T, Souberbielle J-C. High Serum Levels of a non-(1-84) parathyroid hormone (PTH) fragment in pediatric haemodialysis patients. Pediatr Nephrol 2001; 16:1011-1014.

[18] John M, Goodman W, Gao P, Cantor T, Salusky I, Juppner H. A Novel Immunoradiometric Assay Detects Full Length Human PTH but not Amino-Terminally Truncated Fragments: Implications for PTH Measurements in Renal Failure. J Clin Endocrinol Metab 1999; 84(11):4287-4290.

[19] Salusky IB, Goodman WG. Adynamic renal osteodystrophy: is there a problem? J Am Soc Nephrol 2001(Sept); 12(9):1978-85.

[20] Sherrard DJ, Hercz G, Pei Y, Maloney N, Greenwood C, Manuel A, Saiphoo C, Fenton S, Segre G. The spectrum of bone disease in end-stage renal failure—an evolving disorder. Kidney Int 1993(Feb); 43(2):436-42.

[21] Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port K. Association of Elevated Serum PO4, Ca X PO4 Product, and Parathyroid Hormone with Cardiac Mortality Risk in Chronic Hemodialysis Patients. J Am Soc Nephrol 2001; 12:2131-2138.

[22] Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000(Dec); 36(6):1115-1121.

[23] Garner S, Gao P, Cantor T, Leight GS. Potential of a “Whole PTH” Assay to Improve the Discrimination of Intraoperative Parathyroid Hormone Assays. J Bone Miner Res 2000; 15:(Suppl 1) M103.

[24] Gao P, Fulla Y, Scheibel S, Vuillemard C, Cantor T. Recognition of the PTH(7-84) Fragment by 5 Commercial PTH “Sandwich” Assays. J Bone Miner Res 2000; 15: Suppl1. M455.

[25] Goodman WG, Goldin MD, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff R, Salusky I. Coronary-Artery Calcification in Young Adults with End-Stage Renal Disease who are Undergoing Dialysis. N Engl J Med 2000: 342;1478-1483.

[26] Lepage R, Roy L, Brossard J-H, Rousseau L, Dorais C, Lazure C, D’Amour P. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998; 44:(4)805-809.

[27] Malluche HH, Mawad H, Trueba D, Monier-Faugere M-C. Parathyroid hormone assays—evolution and revolutions in the care of dialysis patients. Clin Nephrol 2003; 59(5):313-318.

[28] Santamaria R, Almaden Y, Felsenfeld A, Martin-Malo A, Gao P, Cantor T, Aljama P, Rodriguez M. Dynamics of PTH secretion in hemodialysis patients as determined by the intact and whole PTH assays. Kidney Int 2003; 64:1867-1873.

[29] Ureña P, Bernard-Poenaru O, Ostertag A, Baudoin C, Cohen-Solal M, Cantor T, De Vernejoul MC. Bone mineral density, biochemical markers and skeletal fractures in haemodialysis. Nephrol Dial Transplant 2003(Nov); 18(11):2325-2331.

[30] Barman A. Case Study: When the PTH Ratio Does Not Agree with iPTH or 1-84 PTH. J Am Soc Nephrol 2003(Nov); 14:594.

[31] Faugere MC, Gao P, Geng Z, Cantor TL, Malluche HH. The 1-84:7-84 ratio for determination of bone turnover in chronically dialized patients. J Am Soc Nephrol 2000(Sept); 11.

[32] Lepage R, Rousseau L, Gao P, Cantor T, Brossard J, D’Amour P. Evaluation of the Non-1-84 Fraction of PTH in Renal Failure Using Two IRMA PTH Assays from Scantibodies with Different Specificities. Abstract selected for presentation at the 22nd Annual Meeting of the ASBMR, Sept. 2000, Toronto, CAN. Published: J Bone Miner Res 2000(Sept); 15(Suppl 1):561.

[33] Ghannoum M, Brossard JH, Lepage P, Rousseau L, Cantor T, Gao P, D

Amour P. Threshold for Modulation of C Fragments/hPTH(1-84) Ratio is More Dependent on PTH Level than CA2+ Concentration. Poster #1718 Bone-Calcium-Parathyroid I Poster Session, June 21, 2000, Endocrine Society’s 82nd Annual Meeting, Toronto, CAN Published: J Clin Endocrinol Metab 2000; Suppl: #1718.

[34] Donadio C, Ardini M, Lucchese A. The Relationship Between Glomerular Filtration Rate (GFR) and Plasma Levels of Parathyroid Hormones. J Am Soc Nephrol 2003(Nov); 14:693.

[35] Amerling R. PTH 1-84 and 7-84 in Dialysis Patients Undergoing Bone Biopsy for Suspected Hyperparathyroidism. J Am Soc Nephrol 2003 (Nov); 14:567.

[36] Lindberg JS. A Clinical Update on the New Third Generation Parathyroid Hormone Assays in Dialysis. Cont Dial Nephrol 2002; Oct:38-41.

[37] Waller SC, Ridout D, Cantor T, Rees L. What is the Parathyroid Hormone Level? British Association Paediatric Nephrology 2003 (April) and European Society of Paediatric Nephrology, September 2002, (Ped Nephrol 17:O31 pp C52-3).

[38] Waller SC, Ridout D, Cantor T, Rees, L. Parathyroid Hormone (PTH) in Children with Chronic Renal Failure; relationship between the 1-84PTH:C-PTH Ratio and Growth. J Am Soc Nephrol 2003(Nov); 14:694.

[39] Fulla Y, Vuillemard C, Nonnenmacher L, Gao P, Cantor T, Bonnichon Ph, Chapuis Y. Pre-operative Variation of PTH, PIN and PIN/Total PTH Ratio. Abstract presented at the European Association of Nuclear Medicine, Sept. 2000, Paris, France. Published: 2000(Sept).

[40] Fulla Y, Vuillemard C, Nonnenmacher L, Gao P, Cantor T, Legmann P, Bonnichon Ph, Chapuis Y. Catheter Localization of Parathyroid Adenoma by Determination of PTH and PIN/Total PTH Ratio. Abstract presented at the European Association of Nuclear Medicine, Sept. 2000, Paris, France. Published: 2000(Sept).

[41] Nguyen-Yamamoto L, Rousseau L, Brossard J-H, Lepage R, Gao P, Cantor T, D’Amour P. Origin of parathyroid hormone (PTH) fragments detected by intact-PTH assays. Euro J Endocrinol 2002(Jul); 147(1):123-31.

[42] Gao P, Cantor T, D’Amour P, Yamashita H. Duo PTH Assay Kit for the Assessment of a Newly Discovered Circulating Hypocalcemic Parathyroid Hormone (PTH) Fragment in Addition to 1-84 PTH. Abstract Poster presentation for Endo 2002—84th Annual Meeting of the Endocrine Society, June 19-22, 2002, San Francisco, CA. Published Endocrinology, 2002(June).

[43] Gao P, Cantor T, D’Amour P, Yamashita H. The Assessment of a Circulating Hypocalcemic Parathyroid Hormone (PTH) Fragment in Addition to 1-84 PTH in Patients with Hyperparathyroidism Before and After Parathyroidectomy. Award winning abstract and poster presented at the ERA-EDTA World Congress on Nephrology, June 8-12, 2003, Berlin, Germany.

[44] Mere CC, Fehmi H, Llach F. The Effect on The 1-84 PTH/7-84 PTH Ratio By Renagel, Phoslo, Calcium, Tums. J Am Soc Nephrol 2003(Nov); 14:586.

[45] Fehmi H, Long Y, Zasuwa G, Yee J. The Impact of Implementing the 1-84 PTH/7-84 PTH Ratio as a Predictor for Adynamic Low Bone Turnover Disease. J Am Soc Nephrol 2003(Nov); 14:704.

[46] Fehmi H, Yee J, Long Y, Zasuwa G. Changes in Vitamin D Administration Since Implementation of the 1-84 PTH/7-84 PTH Ratio. J Am Soc Nephrol 2003 (Nov); 14:641.

[47] Faugere MC, Mawad HW, Tueba DM, Friedler RM, Malluche HH. Opposite Effects of Calcitriol and Paricalcitol on the PTH-(1-84)/C-Large Fragment Ratio in Patients on Hemodialysis. J Am Soc Nephrol 2003 (Nov); 14:692.

[48] Yamashita H, Gao P, Cantor T, Noguchi S, Uchino S. Watenabi S. Ogawa T, Kawamoto H, Fukagawa M, Noguchi S. Large Carboxy Terminal PTH Fragment is secreted directly from the parathyroid gland in humans with a relatively longer half-life than 1-84 PTH. Eur J Endocrinol 2003; 149:301-306.

[49] Yamashita H, Gao P, Cantor T, Noguchi S, Uchino S, Watenabi S, Ogawa T, Kawamoto H, Fukagawa M. Comparison of parathyroid hormone levels from the intact and whole parathyroid hormone assays after parathyroidectomy for primary and secondary hyperparathyroidism. Surgery 2004; 135:149-56.

[50] Indridason OS, Franzson L, Gao P, Sigurdsson G. PTH and Renal Function. J Am Soc Nephrol 2003(Nov); 14:580.

[51] Cantor, T. How New Discoveries About the Parathyroid Hormone can lead to a Better and Longer Life for Dialysis Patients. For Patients Only 2002: July-August Issue:20-21.

[52] Cantor T. CAP and the CAP/CIP Ratio: The 3rd Generation of PTH Assays for the Prediction of Parathyroid Function and Bone Status. Preliminary Editions published as CAP and CIP, PTH-Mediated Calcium Metabolism: An Elucidation for the Improvement of Clinical Management. 1999. Revised 3rd Generation book published 2001.

[53] Cantor T, Gao P, Acchiardo S. Hypocalcemic 7-84 PTH Fragment Level Decreases with a Decrease in Vitamin D Treatment. J Am Soc Nephrol 2002; 13:752A 406.

[54] Cantor TL, Pasini C. Aspetti clinici innovative della determinazione delle frazioni atticatrici e inibitrici del Paratormone. Ligand Assay 2002(Marzo); 7(1):68-72.

[55] Cantor T, Gao P, Kazama J, Maruyama H, Gejyo F, Acciardo S. The Assay of the Hypocalcemic PTH Fragment Inhibitor with PTH Provides a More Accurate Assessment of Renal Osteodystrophy Compared to the Intact PTH Assay. Abstract Poster presented at the IV Simposio Avances en Osteodistrofia Renal, June 6-7, 2002, Oviedo, Spain. Nefrologia 2003; 23(2):69-72.

[56] Negri AL, Slatopolsky, E. PTH entera: Un Nuevo ensayo para el dosaje de la hormona paratiroidea en pacientes con insuficiencia renal cronica. Nefrologia [2001; 8:(1)54-60.

[57] Gao P, Cantor T, D’Amour P, Yamashita H. The Assessment of a Circulating Hypocalcemic PTH Fragment Level and 1-84 PTH in Patients with Primary and Secondary Hyperparathyroidism Pre- and Post-Parathyroidectomy. J Am Soc Nephrol 2003 (Nov); 14:696.

[58] Cantor T, Glowacki P. Results of 36,047 Patient Values for Intact PTH, 1-84 PTH (CAP), C Terminal PTH Fragments (7-84 PTH) and Ratio. J Am Soc Nephrol 2003(Nov); 14:588.

[59] Cantor T, Scheibel S, Gao P, Lepage R, Cook D, D’Amour P. Duo PTH Assay Kit for the Determination of Human PTH1R Agonist/Antagonist Ratio in Patients with Uremia. Abstract presented in oral presentation at the ERA/EDTA World Congress, June 24-27, 2001, Vienna, Austria. Published: June, 2001.

[60] Cantor T. 3rd Generation Assay for Parathyroid Hormone CAP‘ 1-84 PTH and CIP‘ 7-84 PTH: Implications for Better Patient Management. Hemodialysis 2004; 8:372-385.

[61] Qi Q, Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995; 26:622-31.

[62] Galceran T, Martin KJ, Morrisey JJ, Slatopolsky E. Role of 1.25-dihydroxyvitamin D on the skeletal resistance to parathyroid hormone. Kidney Int 1987; 32:801-807.

[63] Sawaya BP, Faugere M-C, Butros R, Geng Z, Mawad H, Friedler R, Fanti P, Malluche HH. Intact Parathyroid Hormone Levels are not Predictive of Bone Turnover in African-American Patients with ESRD. J Am Soc Nephrol 2001; 12:A4034, 772A.

[64] Salomon R, Charbit C, Gagnadouz M-F, Abdenbi M, Cantor T, Gao P, Niaudet P, Souberbielle J. Serum PTH in Hemodialyzed Children: Implication of Assay Specificity. Abstract presented at the ASN 33 Annual Meeting, Oct. 2002, Toronto, CAN.

[65] Yokoyama K, Tanno Y, Nakayama M, Shigematsu T, Hosoya T, Iwasaki K, Cantor T, Fukagawa M. The Whole PTH Assay is More Useful Parameter than the Common Intact PTH Assay for More Precise Evaluation of Biological PTH Activity on Bone in CAPD Patients. J Am Soc Nephrol 2001; 12:775A, A4050.

[66] Cantor T, Gao P, Scheibel S, Vuillermard C, Fulla Y. The Non-Specificity of Five Intact PTH Assays to Measure Biologically Active PTH in the Chronic Renal Failure Patient. Abstract presented at the ERA/EDTA Annual Congress, June, 2001, Vienna, Austria.

[67] Souberbielle J-C, Cormier C, Kindemans C, Kindermans C, Gao P, Cantor T, Forette F, Baulieu EE. Vitamin D Status and Redefining Serum Parathyroid Hormone Reference Range in the Elderly. J Clin Endocrinol Metab 2001; 86(7):3086-3090.

[68] Gao P, Scheibel S, D’Amour, Cantor T. Measuring the Biologically Active or Authentic Whole Parathyroid Hormone (PTH) with a Novel Immunoradiometric Assay without Cross-Reaction to the PTH(7-84) Fragment. J Bone Miner Res 1999(Sept); 14:SU047,S446.

[69] Brossard JH, Lepage R, Gao P, Cantor T, Rousseau L, D’Amour P. A New Commercial Whole PTH Assay Free of Interference by Non-(1-84) Parathyroid Hormone Fragments in Uremic Samples. Abstract for ASBME 21st Annual Meeting, Sept. 1999, St. Louis, MO.

[70] Gao P, Scheibel SJ, D’Amour, Cantor T. The first immunoradiometric assay exclusively measuring the true biologically active whole parathyroid hormone. Presented at the AACC & ASCLS 52nd Annual Meeting, July 23-27, 2000, San Francisco, CA. Published: Clin Chem CLCHAU (S6) Part 2 of 2, A120, #459.

[71] Lepage R, Brossard J-H, Gao P, Cantor T, Rousseau L, D’Amour P. Comparative evaluation of a whole-PTH assay free from interference by non-(1-84)PTH. Presented at the AACC & ASCLS 52nd Annual Meeting, July 23-27, 2000, San Francisco, CA. Published: Clin Chem CLCHAU (S6) Part 2 of 2, A121, #462.

[72] Kifor O, Cantor T, Kifor I, Butters R, Delaney M, Moore FD, Garber J, Hendy G, Sterpka J, Philbrick W, Gao P, Brown EM, Wysolmerski J. Autoimmune Familial Hypocalcemia (FHH) caused by Blocking Autoantibodies to the Calcium-Sensing Receptor (CaR). Abstract for the 22nd Annual Meeting of the ASBMR, Sept. 2000, Toronto, CAN. Published: J Bone Miner Res 2000; 15:(Suppl 1)S165, #1106.

[73] Souberbielle J, Cormier C, Kindermans C, Bonnet P, Herviaux P, Cantor T, Gao P, Forette F, Baulieu E. Reference Data for Serum PTH should take the Vitamin D Status into Account: Lessons of the DHEage study. Abstract for the 22nd Annual Meeting of the ASBMR, Sept. 2000, Toronto, CAN. Published:

J Bone Miner Res 2000; 15:(Suppl 1)S445, #SU472.

[74] Gao P, Scheibel S, Liu W, et al. Assessment of Amino-Terminally Truncated PTH Fragment Using Two Novel PTH IRMAs Sharing Universal Solid-Phase and Calibrators. Abstract for the 22nd Annual Meeting of the ASBMR, Sept. 2000, Toronto, CAN. Published: J Bone Miner Res 2000; 15:(Suppl 1)S446, #SU475.

[75] Reichel H, Roth HJ, Krug A, Gao P, Schmidt-Gayk H, John MR. Correlation Between a Novel Assay for Full-Length Parathyroid Hormone (PTH), Intact PTH, Tartrate-Resistant Acid Phosphatase and Bone Alkaline Phosphatase in Adult Hemodialysis Patients. Abstract for the 22nd Annual Meeting of the ASBMR, Sept. 2000, Toronto, CAN. Published: J Bone Miner Res 2000; 15:(Suppl 1)S448, #SU485.

[76] Souberbielle JC, Cormier C, Belbachir SA, Bonnet P, Herviaux P, Cantor T, Gao P, Kindermans C. Evaluation of a New PTH Assay Specific Only for the 1-84 PTH. Abstract for the 22nd Annual Meeting of the ASBMR, Sept. 2000, Toronto, CAN. Published: J Bone Miner Res 2000; 15:(Suppl 1)S481, #M100.

[77] Kwan JT, McGee G, Sims B, et al. Diurnal Variations in 1-84 PTH (iPTH) and 7-84 PTH (PIN) Secretion in Haemodialysis Patients. Abstract presented at the ASN Annual Meeting, Oct. 2000, Toronto, CAN. Published J Amer Soc Nephrol 2000; 11:3047.

[78] Brossard JH, Lepage R, Cardinal H, Roy L, Rousseau L, Dorais C, D’Amour P. Influence of Glomerular Filtration Rate on Non-(1-84) Parathyroid Hormone (PTH) Detected by Intact PTH Assays. Clin Chem 2000; 46:(5)697-703.

[79] DeGroot LJ, Jameson JL, et al. N-Terminally Truncated Fragments of PTH. Endocrinology 4th Edition, pp. 978.

[80] Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, D’Amour P. Synthetic Carboxyl-Terminal Fragments of Parathyroid Hormone (PTH) Decrease Ionized Calcium Concentration in Rats by Acting on a Receptor Different from the PTH/PTH-Related Peptide Receptor. Endocrinology 2001; 142:(4)1386-1392.

[81] The Parathyroids, 2nd Edition, Bilezikian J, Editor-in-Chief, Marcus R, & Levine MA, editors. Academic Press, San Diego, CA 2001.

[82] Nakanishi S, Kazama JJ, Shigematsu T, Iwasaki Y, Cantor T, Kurosawa T, Fukagawa M. Comparison of Intact PTH Assay and Whole PTH Assay in Long Term Dialysis Patients. Am J Kidney Dis 2001; 38:S172-S174, #90041.

[83] Silverberg S, Shane E, Jacobs T, Siris E, Bilezikian J. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. New Engl J Med 2000; 341:1249-1256.

[84] Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid mediated osseus abnormalities in uremia. J Clin Endocrinol Metab 1992; 75:145-150.

[85] Kazama JJ, Gejyo F, Shigematsu T, Fukagawa M. Uremia Increases Circulating 7-84 PTH Level. Abstract A-4007, presented at ASN Annual Meeting Poster Session Oct. 2001. Published: J Am Soc Nephrol 2001; 12:SUI-0853.

[86] Kazama JJ, Maruyama H, Gejyo F, Gao P, Cantor T. Hypocalcemic 7-84 PTH Fragment level Increases with Vitamin D Treatment. Abstract submitted for ERA/EDTA Annual Congress, July 2002, Copenhagen, Denmark.

[87] Loveridge N, Fischer JA, Nagant de Deuxchaisnes C, Dambacher MA, Tschopp F, Werder E, Devogelaer JP, de Meyer R, Bitensky L, Chayen J. Inhibition of cytochemical bioactivity of parathyroid hormone by plasma in pseudohypoparathyroidism type 1. J Clin Endocrinol Metab 1982(Jun); 54(6):1274-1275.

[88] Martin K, Gonzalez E. The Evolution of Assays for Parathyroid Hormone. Curr Opin Nephrol Hypertens 2001(Sept); 10(5):569-574.

[89] Cantor T, Gao P, Niederle B, Prager G, Bieglmayer C. The half-lives of Circulating 1-84 PTH & 7-84 PTH and the Selection of the Best Assay Mode for Intra-Operative Parathyroidectomy Monitoring. Abstract presented at Endo’ 2002 Annual Meeting, June 2002, San Francisco, CA.

[90] Kazama J, Omori K, Maruyama H, et al. Maxacalcitol Therapy Suppresses Hyperactive Parathyroid Function with a Predominant Reduction of Authentic 1-84 PTH and a Lessor Reduction of Large C Terminal PTH Fragments in Dialysis Patients—Potential Explanation for Adynamic Bone following Vitamin D. J Amer Soc Nephrol 2002; 13:571A,SU-PO505.

[91] Cohen A, LoGerfo P, Gao P, Cantor T. PTH(1-84) and N-truncated PTH Fragment in the Serum and Parathyroid Glands of Patients with Primary Hyperparathyroidism. J Bone Miner Res 2001(Sept); 16:(Suppl 1)S156.

[92] Ritz E, Mehls O, Bommer J, Schmidt-Gayk H, Fiegel P, Reitinger H. Vascular Calcifications Under Maintenance Hemodialysis. Klinische Wochen-schrift 1977; 55:375-378.

[93] Cohen A, Addonizio LJ, Lamour JM, Gao P, Shane E. Osteoporosis in Adult Survivors of Pediatric Cardiac Transplantation may be Related to Hyperparathyroidism, Mild Renal Insufficiency and Increased Bone Turnover. J Bone Miner Res 2003; 18:SA439.

[94] Gao P, Scheibel S, Hakim K, Cantor T. Cloning and Expression of Fourteen N-terminally Truncated PTH Fragments and their use for the Validation of Assay Specificities. J Bone Miner Res 2003; 18:SA422.

[95] Rubin M, Gao P, Cantor T, Bilezikian JP, Silverberg S. Parathyroid Hormone is Modified in Parathyroid Carcinoma: A Novel N-Terminally Intact Hormone with Different Immunoreactivity from PTH(1-84). J Bone Miner Res 2003; 18:M411.

[96] Rakel A, Rousseau L, Albert C, Brossard JH, Cantor T, Gao P, D’Amour P. Influence of Amino-terminal PTH Assay Epitopes on Normal Parathyroid Function Measurements. J Bone Miner Res 2003; 18:M440.

[97] Brossard J, Rakel A, Rousseau L, Cantor T, Gao P, D’Amour P. Comparison of Four Immunometric PTH Assay Results in Primary and Secondary Hyperparathyroidism. An HPLC Validation. J Bone Miner Res 2003; 18:M443.

[98] Cantor T, Scheibel S, Glowacki P. Differences in Correlations Between Nichols Bio-Intact PTH Assay to the Nichols IRMA Intact PTH Equivalent Assay vs Nichols Advantage Intact PTH Assay. J Am Soc Nephrol 2003(Nov); 14:584.

[99] Cantor T, D’Amour P. Comparison between the Nichols Manual IRMA Intact PTH Assay and the Nichols Automated Advantage Intact PTH Assay. J Am Soc Nephrol 2003(Nov); 14:585.

[100] Cantor T, Scheibel S, Glowacki, P. Nonalignment of the Nichols IRMA Intact PTH Assay with the Nichols Advantage Intact PTH Assay: Implications for K/DOQI Dosing for Vitamin D Sterols Guidelines. J Am Soc Nephrol 2003(Nov); 14:587.

[101] Cantor T, Rubin MR, Bilezikian J, Gao P, Silverberg S. A Novel Form of Parathyroid Hormone found in Parathyroid Carcinoma with a Preserved N Terminus. J Am Soc Nephrol 2003(Nov); 14:589.

[102] Cantor T, Glowacki P, D’Amour P. Comparison between the Nichols and Scantibodies IRMA PTH Assays of 1999 and 2003 for Stored Samples. J Am Soc Nephrol 2003(Nov); 14:590.

[103] Cantor T, Scheibel S, Glowacki, P. Nonalignment of the Nichols IRMA Intact PTH Assay with the Nichols Advantage Intact PTH Assay: Implications for K/DOQI Diagnosis and Treatment. J Am Soc Nephrol 2003(Nov); 14:591.

[104] Cantor T, Amerling R. The Effect of Freeze/Thaw of Whole Blood on PTH Test Values—PTH Specimen Transportation Study. J Am Soc Nephrol 2003(Nov); 14:592.

[105] Cantor T, Glowacki P, Scheibel S. Under Recovery of the DiaSorin Intact PTH Assay: Implications for K/DOQI Diagnosis, Treatment and Dosing of Vitamin D Sterols. J Am Soc Nephrol 2003(Nov); 14:593.

[106] Nakayama Y, Nonoguchi H, Inoue T, Kohda Y, Maruse M, Hirayama H, Ishimatsu T, Tanaka M, Itoh K, Matsushita K, Tazeo N, Tajiri M, Ikezaki N, Shimomura T, Nakayama M, Tsuruta K, Ogasawara H, Ogawa A, Tomita K. Long-Term Calcitriol Injection Therapy Using the CAP as a Marker (A New Strategy to Reach the Ideal level of PTH). J Am Soc Nephrol 2003(Nov); 14:595.

[107] Sawaya BP, Faugere M-C, Friedler RM, Malluche. Racial Differences in Bone Response to Calcitriol Therapy in ESKD Patients. J Am Soc Nephrol 2003(Nov); 14:644.

[108] Cantor T, Glowacki P, Scheibel S. Similarities and Differences Between the 1-84 PTH Specific Assays: Scantibodies CAP Assay vs the Nichols Bio-Intact Assay. J Am Soc Nephrol 2003(Nov); 14:697.

[109] Cantor T, Glowacki P, Scheibel S. Large Differences Between Commercial Intact PTH Assays. J Am Soc Nephrol 2003(Nov); 14:698.

[110] D’Amour P, Brossard J-H, Rousseau L, Roy L, Gao P, Cantor T. Amino-Terminal Form of Parathyroid Hormone (PTH) with Immunologic Similarities to hPTH(1-84) is Overproduced in Primary and Secondary Hyperparathyroidism. Clin Chem 2003; 49:12,2037-2044.

[111] Tanno Y, Yokoyama K, Nakayama M, et al. IRMA (whole PTH) is a more useful assay for the effect of PTH on bone than the Allegro intact PTH assay in CAPD patients with low bone turnover marker. Nephol Dial Transplant 2003(Jun), 28:Suppl 3,iii97-98.

[112] Kifor O, Kifor I, Moore FD Jr, Brown E, Cantor T, Gao P. Decreased expression of caveolin-1 and altered regulation of mitogen-activated protein kinase in cultured bovine parathyroid cells and human parathyroid adenomas. J Clin Endocrinol Metab 2003(Sep); 88(9):4455-64.

[113] Yamashita H, Gao P, Noguchi S, Cantor T, Uchino S, Watanabe S, Yamashita H. Role of cyclase activating parathyroid hormone (1-84 PTH) measurements during parathyroid surgery: potential improvement of intraoperative PTH assay. Ann Surg 2002(Jul); 236(1):105-111.

[114] Estepa JC, Garfia B, Gao P, Cantor T, Rodriguez, Aguilera-Tejero E. Validation and Clinical Utility of a Novel Immunoradiometric Assay exclusively for biologically active whole parathyroid hormone in the horse. Equine Vet J 2003(May); 35(3):291-5.

[115] Estepa JC, Lopez I, Felsenfeld AJ, Gao P, Cantor T, Rodriguez M, Aguilera-Tejero A. Dynamics of secretion and metabolism of PTH during hypo-and hypercalcemia in the dog as determined by the “intact” and “whole” PTH assays. Nephrol Dial Transplant 2003(Jun); 18(6):1101-7.

[116] Kifor O, Moore FD Jr. Delaney M, Brown E, Cantor T, Gao P. A Syndrome of hypocalciuric hypercalcemia caused by autoantibodies directed at the calcium-sensing receptor. J Clin Endocrinol Metab 2003(Jan); 88(1):60-72.

[117] Ilamathi E, Moore B, Finger M, Cariani N, Kirsh M, Angeles, C. The Scantibodies CAP/CIP Ratio Identifies 40% more Adynamic Bone Disease Patients than the Scantibodies Total Intact PTH, CAP Alone, or Nichols Bio-Intact PTH Assays. Am J Kidney Dis 2004; 43(4).

[118] Tokumoto A, Amerling R. Bone Histology Demonstration of the Utility of the CAP/CIP Ratio to Accurately Discriminate Adynamic Bone Disease from High Bone Turnover Disease with the Similar 1-84 PTH Values. Am J Kidney Dis 2004; 43(4).

[119] Rozas V. New PTH Assays—Do They Really Make a Diagnostic Difference? Am J Kidney Dis 2004; 43(4).

[120] Donadio C, Cantor T. The Difference in the Scantibodies CAP/CIP Ratios Between Stage 1 and Stage 2 Pre-ESRD Patients. Am J Kidney Dis 2004; 43(4).

[121] Cantor T. Unexplained Increase in Parathyroidectomies in the U.S. Since 1998. Am J Kidney Dis 2004; 43(4).

[122] Ashfaq A, Mossey R, Bellucci A, Miller I, Latcha S, Gitman M, Mallappallil M. The Relationship Between the CAP/CIP Ratio and Serum Calcium. Am J Kidney Dis 2004; 43(4).

[123] Ashfaq A, Mossey R, Bellucci A, Miller I, Latcha S, Gitman M, Mallappallil M.The Relationship Between CAP (1-84 PTH and Serum Calcium. Am J Kidney Dis 2004; 43(4).

[124] Ashfaq A, Mossey R, Bellucci A, Miller I, Latcha S, Gitman M, Mallappallil M. Comparison Between the Scantibodies Total Intact PTH Assay and the Nichols Advantage PTH Assay. Am J Kidney Dis 2004; 43(4).

[125] Amerling R. Treatment Protocol Using Doxercalciferol (Hectorol) and CAP and the CAP/CIP Ratio. Am J Kidney Dis 2004; 43(4).

[126] Amerling R. Treatment Protocol Using Doxercalciferol (Hectorol) and Intact PTH and the CAP/CIP Ratio. Am J Kidney Dis 2004; 43(4).

[127] Amerling R. Diagnostic Probability Guideline for the CAP/CIP Ratio. Am J Kidney Dis 2004; 43(4).

[128] Amerling R. Calcium x Phosphate Control—The Benefit of the Scantibodies CAP/CIP Ratio. Am J Kidney Dis 2004; 43(4).

[129] Amerling R. Bone Histology from 7 ESRD Patients Confirmed that no Patient with Hyperparathyroidism had a CAP/CIP Ratio of <1.5. Am J Kidney Dis 2004; 43(4).

[130] Old, C. A Summary of Scantibodies PTH Test Results Measuring the Intact PTH, 1-84PTH, C-Terminal PTH Fragments (7-84PTH) and the Ratio. Am J Kidney Dis 2004; 43(4).

[131] Cantor T, Glowacki P and Scheibel S. Large Differences Between Commercial Intact PTH Assays. Selected for presentation & publication ENDO 2004 Clinical Meeting.

[132] Cantor T, Yamashita H, Noguchi S. The Physiological Role of Large Carboxyterminal PTH Fragments in Primary Hyperparathyroidism. Selected for presentation & publication ENDO 2004 Clinical Meeting.

[133] Cantor T, Waller S, Rees L, Ridout D. The Relationship Between the 1-84PTH:7-84PTH Ratio and Growth in Children with Chronic Renal Failure. Selected for presentation & publication ENDO 2004 Clinical Meeting.

[134] Amerling R. Improving Calcium x Phosphate Through Use of the Scantibodies 1-84 PTH/7-84 PTH Ratio. ERA/EDTA World Congress, 2004.

[135] Omar H, Chamberlin A, Walker V, Wood PJ. Immulite 2000 parathyroid hormone assay: stability of parathyroid hormone in EDTA blood kept at room temperature for 48 hours. Ann Clin Biochem 2001(Sep); 38Pt5:561-3.

[136] NCCLS- Procedures for the Handling and Processing of Blood Specimens; Approved Guideline—Second Edition. H18-A2, Vol. 19, No. 21. (Replaces H18-A) Vol. 10, No. 12, October, 1999.

[137] Advantage™ Assay Directional Insert, Nichols Institute Diagnostics.

[138] CAP™ Assay Directional Insert, Scantibodies Laboratory, Inc.

[139] Total Intact PTH™ Directional Insert, Scantibodies Laboratory, Inc.

[140] Cantor T. The Importance of Correct Specimen Preparation and Transport in the Accurate Measurement of PTH. Dial & Transplant 2003(Nov); 32:(11)711-715.

[141] Nussbaum SR, Zahradnik RI, LaVigne JR, et al. Highly sensitive two-site immunoradiometric assay of parathyrin and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987; 33:1364-1367.

[142] Rosenblatt M. Parathyroid Hormone: Effects of the 3-34 Fragment in vivo and in vitro. Science 1983; 219:4580,67-69.

[143] Teng M, Wolf M, Lowrie E. Survival of Patients Undergoing Hemodialysis with Paricalcitol or Calcitriol Therapy. N Engl J Med 2003; 349:446-56.

[144] Silverberg A, Brown J, Bilezikian J, Deftos LJ. A New Highly Sensitive Assay for Parathyroid Hormone in Primary Hyperparathyroidism. J Bone Miner Res 2000(Sep); 15:Suppl 1, #1116, S167.

[145] Mayer GP, Habener JF, Potts JT Jr. Parathyroid hormone secretion in vivo. Demonstration of a calcium-independent non-suppressible component of secretion. J Clin Invest 1976(Mar); 57(3):678-683.

[146] Massry SG, Cobern JW, Lee DB. Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects. Ann Intern Med 1973(Mar); 78(3):357-364.

[147] Loveridge N, Fischer JA, Devogelaer JP. Suppression of parathyroid hormone inhibitory activity of plasma in pseudohypoparathyroidism type I by i.v. calcium. Clin Endocrinol (Oxf). 1986(May); 24(5):549-554.

[148] Habener FJ, Segre GV, Powell D. Immunoreactive parathyroid hormone in circulation of man. Nat New Biol 1972(Aug 2); 238(83):152-154.

[149] Jarava C, Armas JR, Palma A. Study of Renal Osteodystrophy by Bone Biopsy. Age as an independent factor. Diagnostic value of bone remodeling markers. Nefrologia 2000(Jul-Aug); 20(4):362-72.

[151] Kazama J, Omori K, Higuchi N, Takahashi N, Ito Y, Maruyama H, Narita I, Cantor T, Gao P, Gejyo F. Intact PTH assay overestimates true 1-84 PTH levels after Maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism. Neph Dial Transplant 2004; 19:892-897.

[152} Stevens L, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, Phosphate, and Parathyroid Hormone Levels in Combination and as a Function of Dialysis Duration Predict Mortality: Evidence for the Complexity of the Association between Mineral Metabolism and Outcomes. J Am Soc Nephrol 2004; 15:770-779.

[153] London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, De Vernejoul M-C. Arterial Calcifications and Bone Histomorphometry in End-Stage Renal Disease. J Am Soc Nephrol 2004; 15:1943-1951.

[154] Shin SK, Kim DH, Kim HS, Shin KT, Ma KA, Kim SJ, Kwak YS, Ha SK, Sherrard DJ. Renal Osteodystrophy in Pre-Dialysis Patients: Ethnic Difference? Peritoneal Dial Int 1999, 19:Suppl 2, S402-S407.

©2017 Scantibodies Clinical Laboratory, Inc. 9236 Abraham Way Santee CA, 92071 - (619) 258-9300 (Map) | Terms | Privacy